Related references
Note: Only part of the references are listed.PON1 lactonase activity and its association with cardiovascular disease
F. E. Murillo-Gonzalez et al.
CLINICA CHIMICA ACTA (2020)
Carotid plaques in adult rheumatoid arthritis patients; association with paroxonase 1 enzymatic activity and Q192R paroxonase 1 gene polymorphism
Essam Tawfik Atwa et al.
MOLECULAR BIOLOGY REPORTS (2020)
Reactive Dicarbonyl Scavenging Effectively Reduces MPO-Mediated Oxidation of HDL and Restores PON1 Activity
Jiansheng Huang et al.
NUTRIENTS (2020)
Scavenging of reactive dicarbonyls with 2-hydroxybenzylamine reduces atherosclerosis in hypercholesterolemic Ldlr-/- mice
Huan Tao et al.
NATURE COMMUNICATIONS (2020)
Relationship of High-Density Lipoprotein-Associated Arylesterase Activity to Systolic Heart Failure in Patients with and without Type 2 Diabetes
Chang Li et al.
SCIENTIFIC REPORTS (2019)
Circulating Lactonase Activity but Not Protein Level of PON-1 Predicts Adverse Outcomes in Subjects with Chronic Kidney Disease
Chrysan J. Mohammed et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Modified sites and functional consequences of 4-oxo-2-nonenal adducts in HDL that are elevated in familial hypercholesterolemia
Linda S. May-Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Electron Paramagnetic Resonance Measurements of Reactive Oxygen Species by Cyclic Hydroxylamine Spin Probes
Sergey I. Dikalov et al.
ANTIOXIDANTS & REDOX SIGNALING (2018)
Modification by isolevuglandins, highly reactive γ-ketoaldehydes, deleteriously alters high-density lipoprotein structure and function
Linda S. May-Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Molecular Structures of Isolevuglandin-Protein Cross-Links
Wenzhao Bi et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2016)
Neutrophil myeloperoxidase and its substrates: formation of specific markers and reactive compounds during inflammation
Yoji Kato
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION (2016)
Effects of paraoxonase 1 gene polymorphisms on heart diseases Systematic review and meta-analysis of 64 case-control studies
Yazmin Hernandez-Diaz et al.
MEDICINE (2016)
Toward Understanding the Catalytic Mechanism of Human Paraoxonase 1: Site-Specific Mutagenesis at Position 192
Geetika Aggarwal et al.
PLOS ONE (2016)
Accumulation of isolevuglandin-modified protein in normal and fibrotic lung
Stacey Mont et al.
SCIENTIFIC REPORTS (2016)
Modification of platelet proteins by malondialdehyde: prevention by dicarbonyl scavengers
Irene Zagol-Ikapite et al.
JOURNAL OF LIPID RESEARCH (2015)
Association between PON1 rs662 polymorphism and coronary artery disease
T. Liu et al.
EUROPEAN JOURNAL OF CLINICAL NUTRITION (2014)
Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex
Ying Huang et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme
Priyanka Bajaj et al.
PROTEIN SCIENCE (2013)
Association between PON1 activity and coronary heart disease risk: A meta-analysis based on 43 studies
Yuan Zhao et al.
MOLECULAR GENETICS AND METABOLISM (2012)
Studies on protective effects of human paraoxonases 1 and 3 on atherosclerosis in apolipoprotein E knockout mice
C. Zhang et al.
GENE THERAPY (2010)
Pomegranate juice polyphenols increase recombinant paraoxonase-1 binding to high-density lipoprotein: Studies in vitro and in diabetic patients
Bianca Fuhrman et al.
NUTRITION (2010)
Sequential Mannich-Aza-Michael Reactions for the Stereodivergent Synthesis of Highly Substituted Pyrrolidines
Charlotte Enkisch et al.
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2009)
Modification of High Density Lipoprotein by Myeloperoxidase Generates a Pro-inflammatory Particle
Arundhati Undurti et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity
Leonid Gaidukov et al.
JOURNAL OF LIPID RESEARCH (2007)
Pyridoxamine analogues scavenge lipid-derived γ-ketoaldehydes and protect against H2O2-mediated cytotoxicity
Sean S. Davies et al.
BIOCHEMISTRY (2006)
Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome
Bharti Mackness et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease
M Granér et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases
O Khersonsky et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases
O Khersonsky et al.
CHEMBIOCHEM (2006)
High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I
L Gaidukov et al.
BIOCHEMISTRY (2005)
Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities
DI Draganov et al.
JOURNAL OF LIPID RESEARCH (2005)
Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase
O Khersonsky et al.
BIOCHEMISTRY (2005)
Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages
L Zheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The 'evolvability' of promiscuous protein functions
A Aharoni et al.
NATURE GENETICS (2005)
A simplified synthesis of the diastereomers of Levuglandin E-2
V Amarnath et al.
SYNTHETIC COMMUNICATIONS (2005)
Separation and quantitative recovery of mouse serum arylesterase and carboxylesterase activity
PW Connelly et al.
JOURNAL OF LIPID RESEARCH (2004)
Oxidative modification of low-density lipoprotein: lipid peroxidation by myeloperoxidase in the presence of nitrite
T Kraemer et al.
BIOLOGICAL CHEMISTRY (2004)
Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease
LM Zheng et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Prognostic value of myeloperoxidase in patients with chest pain
M Brennan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Model studies on protein side chain modification by 4-oxo-2-nonenal
WH Zhang et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2003)
Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo
E Poliakov et al.
FASEB JOURNAL (2003)
Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation
RL Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Defects in leukocyte-mediated initiation of lipid peroxidation in plasma as studied in myeloperoxidase-deficient subjects: systematic identification of multiple endogenous diffusible substrates for myeloperoxidase in plasma
RL Zhang et al.
BLOOD (2002)
Paraoxonase status in coronary heart disease - Are activity and concentration more important than genotype?
B Mackness et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation
DI Draganov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis
DM Shih et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions - PON1 esterase and peroxidase-like activities
M Aviram et al.
CIRCULATION (2000)
Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease
RW James et al.
CIRCULATION (2000)
Share Paper
